Ultrasound-guided care for people with chronic heart failure
Tests ultrasound-guided treatment against standard blood-test care in people with heart failure.
Plain-language title generated from the registry record
Registry title: Point-of-Care Ultrasound in Chronic Heart Failure
Key facts
- Where
- Brno, CzechiaSee the site
Where in Czechia
- University Hospital BrnoBrno, CzechiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Masaryk University
- Trial code
- NCT06887179
- Record updated
- 25 March 2025
- Original description
This study aims to determine whether Point-of-Care Ultrasound (POCUS)-guided treatment is non-inferior to standard NT-proBNP-based care in ambulatory patients following hospitalization for heart failure (HF) over a 12-month follow-up period.Read full original descriptionShow less
The Role of Point-of-Care Ultrasound in the Management of Chronic Heart Failure
This study aims to determine whether Point-of-Care Ultrasound (POCUS)-guided treatment is non-inferior to standard NT-proBNP-based care in ambulatory patients following hospitalization for heart failure (HF) over a 12-month follow-up period.
Inclusion: Patients after hospitalization for acute heart failure (AHF); Symptoms (shortness of breath, oedema, decreased exercise tolerance, increase in abdominal circumference); Clinical signs (jugular vein distention, hepatojugular reflux, third heart sound, wet lung crackles, pitting oedema) or signs of congestion on CT, X-ray or ultrasound; NT-proBNP >450 pg/mL <55 years old, >900 pg/mL 55-75 years old, >1800 pg/mL >75 years old; Increase in oral diuretic therapy or need for IV diuretics.
Exclusion: planned surgical treatment of the HF cause, CRT implantation or valvular repair ≤ 30 days ago, STEMI or coronary angiography with PCI or CABG ≤ 30 days ago, untreated AV block III. and II. degree type 2, planned or previous heart transplantation, myocarditis ≤ 6 months ago, complex congenital heart disease, cardiac amyloidosis, hypertrophic and restrictive cardiomyopathy, constrictive pericarditis; current AHF due to a transient cause (Takotsubo syndrome, neurogenic myocardial stunning, septic cardiomyopathy, cardiac tamponade, pulmonary embolism with acute cor pulmonale, thyrotoxicosis, bradycardia <40/min); BMI over 40 kg/m2, cognitive deficit with MMSE <18 points, life expectancy < 12 months, progressive oncological disease, chronic liver failure Child-Pugh C, chronic kidney disease with eGFR <0.25 ml/s; under 18 years of age,; pregnancy or lactation; current participation in another study or relative of investigators.